These findings suggested that GSTM1 null, GSTP1 null and GSTT1 null polymorphisms may have the potential to serve as genetic biomarkers of CAD and they may be used to identify subjects at higher risk of developing CAD. The gene discussed is GSTM1; the disease is coronary artery disorder.